Introduction
Innovative Next Generation Sequencing (NGS) makes it possible to simultaneously sequence a large number of genes instead of using conventional gene-by-gene analysis. The detection of targeted mutations in cancer cell genes enables more accurate diagnosis, prognosis and treatment for a particular type of cancer. NGS therefore allows more targeted cancer treatment to be offered.
Objective
NGS data are registered by laboratories that have an agreement with the Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (National Institute for Health and Disability Insurance) using the PITTER online registration tool, managed by Healthdata.be and Sciensano’s Cancer Centre, and is a requirement to obtain reimbursement. The project database contains patient test data since 1 July 2019.
Financial support and partners
This registration project is run in collaboration with the RIZIV.
Contact
For more information about this registration project, contact info@kankerregister.org.
